LX4211, a Dual Inhibitor of SGLT2 and SGLT1 Enhances the Effects of Sitagliptin in Patients With Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Zambrowicz, Brian
Ogbaa, Ike
Powell, David
Banks, Phillip
Turnage, Anne
Frazier, Kenny
Boehm, Kristi A.
Freiman, Joel
Lapuerta, Pablo
Sands, Arthur
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
974-P
引用
收藏
页码：A248 / A249
页数：2
相关论文
共 50 条
  • [41] Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?
    Milton Packer
    Nature Cardiovascular Research, 2023, 2 : 705 - 707
  • [42] Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?
    Packer, Milton
    NATURE CARDIOVASCULAR RESEARCH, 2023, 2 (08): : 705 - 707
  • [43] Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care
    Danne, Thomas
    Biester, Torben
    Kordonouri, Olga
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : 69 - 77
  • [44] SGLT2 Inhibitors in Type 2 Diabetes Mellitus
    Ferrannini, Giulia
    Savarese, Gianluigi
    Cosentino, Francesco
    HEART FAILURE CLINICS, 2022, 18 (04) : 551 - 559
  • [45] A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
    Jung, Chang Hee
    Jang, Jung Eun
    Park, Joong-Yeol
    DIABETES & METABOLISM JOURNAL, 2014, 38 (04) : 261 - 273
  • [46] Sodium-glucose cotransporter-2 (SGLT2) inhibitors: improving glycaemic control in patients with type 2 diabetes mellitus (T2DM)
    Blanquez Martinez, David
    Hayon Ponce, Maria
    Caballero Romero, Alvaro
    Gonzalez Medina, Maria del Carmen
    Casas Hidalgo, Inmaculada
    Rodriguez Delgado, Alejandro
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 273 - 273
  • [47] Expression of SGLT1 and SGLT2 in Breast Cancer and Potential Anticancer Effects of SGLT1 Inhibitors
    Tsunokake, Satoko
    Iwabichi, Erina
    Miki, Yasuhiro
    Kanai, Ayako
    Onodera, Yoshiaki
    Ishida, Takanori
    Sasano, Hironobu
    Suzuki, Takashi
    CANCER SCIENCE, 2024, 115 : 1939 - 1939
  • [48] Impact of SGLT2 Inhibitor Tofogliflozin on Hyperinsulinemia and Fatty Liver (FL) through Hepatic Insulin Clearance (HIC) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Matsubayashi, Yasuhiro
    Suganami, Hideki
    Kaku, Kohei
    Sone, Hirohito
    DIABETES, 2016, 65 : A300 - A300
  • [49] LX4211, a Dual Inhibitor of SGLT1/SGLT2, Increases GLP-1 and PYY in Healthy Subjects Regardless of Dose Timing Relative to Breakfast; GLP-1 Elevations are Greatest when Dosed Just Prior to Breakfast
    Ogbaa, Ike
    Powell, David
    Banks, Phillip
    Turnage, Anne
    Frazier, Kenny
    Boehm, Kristi A.
    Freiman, Joel
    Sands, Arthur
    Zambrowicz, Brian
    DIABETES, 2012, 61 : A253 - A253
  • [50] Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus
    Ribola, F. A.
    Cancado, F. B.
    Schoueri, J. H. M.
    De Toni, V. F.
    Medeiros, V. H. R.
    Feder, D.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (01) : 199 - 211
12345